Loss-of-function, gain-of-function and dominant-negative mutations have profoundly different effects on protein structure

被引:0
|
作者
Lukas Gerasimavicius
Benjamin J. Livesey
Joseph A. Marsh
机构
[1] University of Edinburgh,MRC Human Genetics Unit, Institute of Genetics & Cancer
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Most known pathogenic mutations occur in protein-coding regions of DNA and change the way proteins are made. Taking protein structure into account has therefore provided great insight into the molecular mechanisms underlying human genetic disease. While there has been much focus on how mutations can disrupt protein structure and thus cause a loss of function (LOF), alternative mechanisms, specifically dominant-negative (DN) and gain-of-function (GOF) effects, are less understood. Here, we investigate the protein-level effects of pathogenic missense mutations associated with different molecular mechanisms. We observe striking differences between recessive vs dominant, and LOF vs non-LOF mutations, with dominant, non-LOF disease mutations having much milder effects on protein structure, and DN mutations being highly enriched at protein interfaces. We also find that nearly all computational variant effect predictors, even those based solely on sequence conservation, underperform on non-LOF mutations. However, we do show that non-LOF mutations could potentially be identified by their tendency to cluster in three-dimensional space. Overall, our work suggests that many pathogenic mutations that act via DN and GOF mechanisms are likely being missed by current variant prioritisation strategies, but that there is considerable scope to improve computational predictions through consideration of molecular disease mechanisms.
引用
收藏
相关论文
共 50 条
  • [31] Unraveling the immunogenetics of STAT proteins: Clinical perspectives on gain-of-function and loss-of-function variants
    Meesilpavikkai, Kornvalee
    Hirankarn, Nattiya
    Dalm, Virgil A. S. H.
    van Hagen, P. Martin
    Dik, Willem A.
    Ijspeert, Hanna
    ASIAN PACIFIC JOURNAL OF ALLERGY AND IMMUNOLOGY, 2024, 42 (02): : 105 - 122
  • [32] Characterization of a new mouse p53 variant: loss-of-function and gain-of-function
    James Yi-Hsin Chan
    Ying-Chuan Chen
    Shu-Ting Liu
    Wei-Yuan Chou
    Ching-Liang Ho
    Shih-Ming Huang
    Journal of Biomedical Science, 21
  • [33] Highly efficient CRISPR systems for loss-of-function and gain-of-function research in pear calli
    Ming, Meiling
    Long, Hongjun
    Ye, Zhicheng
    Pan, Changtian
    Chen, Jiali
    Tian, Rong
    Sun, Congrui
    Xue, Yongsong
    Zhang, Yingxiao
    Li, Jiaming
    Qi, Yiping
    Wu, Jun
    HORTICULTURE RESEARCH, 2022, 9
  • [34] Loss-of-function and dominant-negative mechanisms associated with hepatocyte nuclear factor-1β mutations in familial type 2 diabetes mellitus
    Tomura, H
    Nishigori, H
    Sho, K
    Yamagata, K
    Inoue, I
    Takeda, J
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (19) : 12975 - 12978
  • [35] Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities
    Iyer, Swathi V.
    Parrales, Alejandro
    Begani, Priya
    Narkar, Akshay
    Adhikari, Amit S.
    Martinez, Luis A.
    Iwakuma, Tomoo
    ONCOTARGET, 2016, 7 (05) : 5401 - 5415
  • [36] The Jeff Mouse Mutant Model for Chronic Otitis Media Manifests Gain-of-Function as Well as Loss-of-Function Effects
    Kubinyecz, Oana
    Vikhe, Pratik P.
    Purnell, Thomas
    Brown, Steve D. M.
    Tateossian, Hilda
    FRONTIERS IN GENETICS, 2020, 11
  • [37] Efficacy and Safety of Alirocumab in Patients With Autosomal Dominant Hypercholesterolemia Associated With Proprotein Convertase Subtilisin/Kexin Type 9 Gain-of-Function or Apolipoprotein B Loss-of-Function Mutations
    Krempf, Michel
    Hopkins, Paul N.
    Bruckert, Eric
    Lee, Shane
    Donahue, Stephen
    AMERICAN JOURNAL OF CARDIOLOGY, 2020, 125 (06): : 880 - 886
  • [38] Mutations in nebulette have different effects on protein function
    Purevjav, Enkhsaikhan
    Kearney, Debra L.
    DeFreitas, Gilberto
    Taylor, Michael D.
    Varela, Jacquelin
    Carabello, Blase A.
    Labeit, Siegfried
    Murphy, Ross T.
    McKenna, William
    Towbin, Jeffrey A.
    Bowles, Neil E.
    CIRCULATION, 2006, 114 (18) : 167 - 167
  • [39] Pharmacodynamics of Alirocumab in Patients With Autosomal Dominant Hypercholesterolemia Associated With PCSK9 Gain-Of-Function or ApoB Loss-Of-Function Mutations: An Open-Label Extension Study
    Krempf, Michel
    Hopkins, Paul N.
    Bruckert, Eric
    Luc, Gerald
    Lee, Shane
    Donahue, Stephen
    CIRCULATION, 2018, 138
  • [40] Loss-of-function and gain-of-function studies refute the hypothesis that tau protein is causally involved in the pathogenesis of Huntington's disease
    Mees, Isaline
    Li, Shanshan
    Beauchamp, Leah C.
    Barnham, Kevin J.
    Dutschmann, Mathias
    Hannan, Anthony J.
    Renoir, Thibault
    HUMAN MOLECULAR GENETICS, 2022, 31 (12) : 1997 - 2009